HLS Therapeutics Inc. (FRA:74D)

HLS Therapeutics Statistics

Total Valuation

FRA:74D has a market cap or net worth of EUR 94.48 million. The enterprise value is 131.59 million.

Market Cap	94.48M
Enterprise Value	131.59M

Important Dates

The next estimated earnings date is Thursday, March 12, 2026.

Earnings Date	Mar 12, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	31.27M
Shares Outstanding	n/a
Shares Change (YoY)	-0.81%
Shares Change (QoQ)	-0.75%
Owned by Insiders (%)	0.69%
Owned by Institutions (%)	10.78%
Float	18.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.98
PB Ratio	1.80
P/TBV Ratio	n/a
P/FCF Ratio	8.12
P/OCF Ratio	8.02
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.96, with an EV/FCF ratio of 11.32.

EV / Earnings	-10.94
EV / Sales	2.75
EV / EBITDA	8.96
EV / EBIT	n/a
EV / FCF	11.32

Financial Position

The company has a current ratio of 1.17, with a Debt / Equity ratio of 0.88.

Current Ratio	1.17
Quick Ratio	0.81
Debt / Equity	0.88
Debt / EBITDA	3.15
Debt / FCF	3.96
Interest Coverage	-0.55

Financial Efficiency

Return on equity (ROE) is -20.02% and return on invested capital (ROIC) is -2.20%.

Return on Equity (ROE)	-20.02%
Return on Assets (ROA)	-1.86%
Return on Invested Capital (ROIC)	-2.20%
Return on Capital Employed (ROCE)	-3.98%
Revenue Per Employee	517,374
Profits Per Employee	-130,791
Employee Count	92
Asset Turnover	0.36
Inventory Turnover	2.13

Taxes

In the past 12 months, FRA:74D has paid 244,610 in taxes.

Income Tax	244,610
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +21.37% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+21.37%
50-Day Moving Average	3.14
200-Day Moving Average	2.91
Relative Strength Index (RSI)	37.96
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:74D had revenue of EUR 47.60 million and -12.03 million in losses. Loss per share was -0.38.

Revenue	47.60M
Gross Profit	34.18M
Operating Income	-3.96M
Pretax Income	-11.79M
Net Income	-12.03M
EBITDA	14.57M
EBIT	-3.96M
Loss Per Share	-0.38

Balance Sheet

The company has 9.19 million in cash and 46.10 million in debt, giving a net cash position of -36.91 million.

Cash & Cash Equivalents	9.19M
Total Debt	46.10M
Net Cash	-36.91M
Net Cash Per Share	n/a
Equity (Book Value)	52.62M
Book Value Per Share	1.68
Working Capital	3.44M

Cash Flow

In the last 12 months, operating cash flow was 11.79 million and capital expenditures -157,676, giving a free cash flow of 11.63 million.

Operating Cash Flow	11.79M
Capital Expenditures	-157,676
Free Cash Flow	11.63M
FCF Per Share	n/a

Margins

Gross margin is 71.82%, with operating and profit margins of -8.31% and -25.28%.

Gross Margin	71.82%
Operating Margin	-8.31%
Pretax Margin	-24.77%
Profit Margin	-25.28%
EBITDA Margin	30.62%
EBIT Margin	-8.31%
FCF Margin	24.43%

Dividends & Yields

FRA:74D does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.81%
Shareholder Yield	0.81%
Earnings Yield	-12.74%
FCF Yield	12.31%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:74D has an Altman Z-Score of -0.94 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.94
Piotroski F-Score	4